Subscribe to Search results

In early July 2001, Yvette Cooper approved an amended line to take regarding ministers "reviewing the case for compensation".

Published on:

At a meeting of SNBTS and hemophilia directors Professor Ludlam explained 16 haemophilia patients treated with SNBTS Factor 8 had been infected with HTLV 3.

Published on:

At a meeting of SNBTS and heamophilia directors Dr Forbes spoke of findings relating to HTLV 3 antibody seroconversion in a comparative study of haemophilia patients in Glasgow and Denmark.

Published on:

At a meeting of SNBTS and haemophilia directors Dr Brenda Gibson reported five out of ten patients tested at the Royal Hospital for Sick Children (Yorkhill) were HIV positive.

Published on:

At a meeting of SNBTS and haemophilia directors it was agreed that patients should be informed about the recent findings in relation to patients with haemophilia being infected with HIV before additional publicity was given.

Published on:

In 1983 there was an increase in the use of commercial concentrates (200,000 units of Factorate for home treatment), although NHS concentrates remained the mainstay of treatment at the Glasgow Haemophilia Centre.

Published on:

In 1984, the use of commercial concentrates dropped again at the Glasgow Haemophilia Centre.

Published on:

Professor Gordon Lowe confirmed in his oral evidence that he became aware of AIDS cases in haemophiliacs in late 1982 from Professor Forbes who was initiating a study of immune abnormalities in patients with severe haemophilia. The conclusion of the study was that Scottish patients had immunological abnormalities similar to those in their US counterparts.

Published on:

Professor Goron Lowe stated in his oral evidence that Dr Forbes confirmed in his Penrose Inquiry evidence that blood was taken from 77 Scottish people between December 1983 and July 1984, and they were not told that their blood was being tested for HIV. None of the 12 patients who had tested positive had been told of their HIV test results.

Published on:

A study of immune abnormalities in patients with severe haemophilia resulted in the publication in of a paper entitled "Immunological abnormalities in haemophilia: are they caused by American factor VIII concentrate"? The study concluded that Scottish patients had immunological abnormalities similar to those in their US counterparts.

Published on:

It was recorded that 5 young homosexual men had contracted opportunistic infections such as pneumocystis, pneumonia, cryptococcosis or severe candidiasis.

Published on:

Dr Mayne wrote to the Lancet that the evolving HIV problem within the haemophilia population had "caused immeasurable distress to patients and to all physicians treating them. The Doctors concerned were guilty of one fault, namely that of ignorance."

Published on:

In 1985 Dr Mayne listed the following volumes of product usage: In 1982: lmmuno 648,707; Armour 478,137; NHS 12,960. In 1983: Immuno 451,497; Armour 505,844; NHS 159,090. In 1984: Immuno 441,408; Armour 506,184; NHS 525,710.529.

Published on:

Dr Mayne suggested that "It is clear from these figures that the increased use of N.H.S. material should have produced an economy in the purchase of commercial material but, due to extensive orthopaedic surgery being necessary following a series of road traffic accidents and bone fractures, the increase in N.H.S. material was inadequate for needs."

Published on:

It was reported that all three of the patients identified in the July MMWR had died and more cases had been identified, including two patients aged ten or under, leading to the
observation that "children with hemophilia must now be considered at risk for the disease."

Published on:

A patient with severe haemophilia raised concerns regarding the possibility of acquiring AIDS.

Published on:

Professor Bloom stated "there is certainly no need for the haemophilic community to be unduly concerned about this 'new' syndrome. They can rest assured that every effort
is being made to monitor the situation in this country and to collaborate with the Centre for Disease Control in the U.S.A."

Published on:

Dr Evatt wrote to Professor Bloom "The evolution of the epidemic is occurring with a frightening pace...The incidence rate has been increasing in hemophiliacs and the epidemic curve paralays that of the total epidemic curve."

Published on:

It was suggested people with mild haemophilia and von Willebrand disorder DDAVP should be used for minor lesions, or cryoprecipitate or NHS concentrate for other lesions; for children with severe haemophilia cryoprecipitate or NHS concentrate should be used; for adults with severe haemophilia cryoprecipitate should be used.

Published on:

DDAVP featured on the Cardiff Haemophilia centre returns for the first time, and there was no record of its use to any significant extent in 1983. There was a reduction in the use of cryoprecipitate for the treatment of patients with Haemophilia A, with the main treatment product being NHS concentrates (809,972 units) and commercial concentrates (1,051,422 units).

Published on: